Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 36Neoplasms 8Lung Neoplasms 7Neoplasm Metastasis 4Neoplasms by Site 3Lymphoma, Large-Cell, Anaplastic 3Hematologic Neoplasms 3Breast Neoplasms 3Brain Neoplasms 3Thyroid Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms by Histologic Type 2Lymphoproliferative Disorders 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Solid Tumors 1Sexual Dysfunction, Physiological 1Salivary Gland Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Rare Tumour 1Rare Tumor 1Prostatic Neoplasms 1Neuroendocrine Tumors 1

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 81Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25Cystoscopy 24enfortumab vedotin 23Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × alectinib × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡